TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients

~ Initial data from Phase 1b showed Voriconazole Inhalation Powder is Well Tolerated in Asthma Patients ~ Data Supports Progress to Phase 2 and Inclusion of Patients with Asthma

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

1 COMMENT

Cancel reply

Please enter your comment!
Please enter your name here